ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Psychemedics Corporation

Psychemedics Corporation (PMD)

2.32
0.00
(0.00%)
At close: 05 November 8:00AM
2.32
0.00
( 0.00% )
After Hours: 8:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.32
Bid
2.31
Offer
2.33
Volume
13,626
2.32 Day's Range 2.34
1.63 52 Week Range 3.93
Market Cap
Previous Close
2.32
Open
2.34
Last Trade
10
@
2.33
Last Trade Time
08:00:00
Financial Volume
US$ 31,739
VWAP
2.3293
Average Volume (3m)
40,140
Shares Outstanding
5,824,036
Dividend Yield
-
PE Ratio
-3.25
Earnings Per Share (EPS)
-0.71
Revenue
22.1M
Net Profit
-4.15M

About Psychemedics Corporation

Psychemedics Corp is a US-based company that provides testing services for the detection of drugs of abuse through the analysis of hair samples. The core business of the company is performing drug testing and reporting the results. Its drug testing services include training for collection of samples... Psychemedics Corp is a US-based company that provides testing services for the detection of drugs of abuse through the analysis of hair samples. The core business of the company is performing drug testing and reporting the results. Its drug testing services include training for collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit tested of samples. The company also provides testimony to support the results of the tests. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The company operates through a single segment being Drug testing services. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Headquarters
Wilmington, Delaware, USA
Founded
-
Psychemedics Corporation is listed in the Medical Laboratories sector of the NASDAQ with ticker PMD. The last closing price for Psychemedics was US$2.32. Over the last year, Psychemedics shares have traded in a share price range of US$ 1.63 to US$ 3.93.

Psychemedics currently has 5,824,036 shares in issue. The market capitalisation of Psychemedics is US$13.51 million. Psychemedics has a price to earnings ratio (PE ratio) of -3.25.

PMD Latest News

Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing

DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever...

Psychemedics Corporation Launches New Ketamine Hair Testing Service

DALLAS, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, is proud to announce the launch of its new ketamine hair testing solution. This...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.02-0.8547008547012.342.342.31297032.31875939CS
40.010.43290043292.312.342.31179492.31878131CS
120.5531.07344632771.772.3451.68401402.29122895CS
26-0.23-9.019607843142.552.691.63219072.28827879CS
52002.323.931.63168432.51102404CS
156-6.18-72.70588235298.58.91.63130964.42758666CS
260-7.23-75.70680628279.5510.691.63192525.61210612CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
IDAIT Stamp Inc
US$ 0.3636
(49.26%)
7.54M
PTIRGraniteShares 2X Long PLTR Daily ETF
US$ 55.29
(26.55%)
39.94k
ALABAstera Labs Inc
US$ 82.90
(19.16%)
165.52k
BREABrera Holdings PLC
US$ 1.05
(17.98%)
1.28M
CLEUChina Liberal Education Holdings Ltd
US$ 0.2699
(16.84%)
31.79k
MQMarqeta Inc
US$ 4.39
(-26.34%)
228.33k
PRPLPurple Innovation Inc
US$ 0.79
(-15.96%)
71.76k
MYNZMainz BioMed NV
US$ 0.2159
(-10.79%)
4.65k
ABCLAbCellera Biologics Inc
US$ 2.598
(-9.79%)
57.96k
CRUSCirrus Logic Inc
US$ 100.00
(-9.68%)
24.82k
IDAIT Stamp Inc
US$ 0.3621
(48.65%)
7.54M
NVDANVIDIA Corporation
US$ 136.49
(0.29%)
2.98M
ELABElevai Labs Inc
US$ 0.0208
(2.97%)
2.18M
PTONPeloton Interactive Inc
US$ 7.51
(0.13%)
2.04M
ACADAcadia Pharmaceuticals Inc
US$ 14.62
(0.00%)
1.52M

PMD Discussion

View Posts
Simonzx2 Simonzx2 1 year ago
New CEO, turnaround?
👍️0
deet49 deet49 4 years ago
It's A Match! Evidence for the transfer of methadone and EDDP by sweat to children’s hair Published: 05 April 2021

https://link.springer.com/article/10.1007/s00414-021-02576-1

Sweat patches (PharmCheck Sweat Patch Kit) were purchased from PharmChem Inc. (Fort Worth, TX, USA).

PMD PCHM TRCK BLOZF


👍️0
deet49 deet49 4 years ago
was relying on my platform for ER dates usually reliable but the date has moved again for PMD I was more interested in the peripheral information for another stock I / we follow closely buyout / merger / SPAC ....?
👍️0
LMLYP LMLYP 4 years ago
If you want to call up and ask if there is a conference call, the phone number for corporate is attached.

https://investors.psychemedics.com/corporate-profile/default.aspx
👍️0
deet49 deet49 4 years ago
Correction today: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162615055 AH
👍️0
LMLYP LMLYP 4 years ago
PMD class L has 3.4 million outstanding. My bad. Long day.
If anyone owns PMD or is watching, there is no such thing as PMD class L.
We're talking about another symbol. Tough to figure out.
👍️0
deet49 deet49 4 years ago
is that the right share structure you sent me PMD L
I see Outstanding Shares
3,376,000
👍️0
LMLYP LMLYP 4 years ago
I'm not in it, but as a PCHM owner, I have no choice but to watch PMD.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160487750


PCHM
👍️0
deet49 deet49 4 years ago
everyone~loves a~Good growth~stock that~Pays Divideneds

does PMD have the cash or would they have to raise to buy out a PCHM?
no not the PMDL board could be very attractive to say the right buyer...
👍️0
LMLYP LMLYP 4 years ago
Is this the PMDL board? I didn't think so.

A PMD long story could be put together but I think it is best to wait for guidance. The activist investor who took a stake in PMD has to know about PCHM too.


👍️0
LMLYP LMLYP 4 years ago
Quite a move.
👍️0
LMLYP LMLYP 4 years ago
CFO left (J knew). Read next quarterly. Watch insider activity. Feel the chart. Engage Cheddar. Deet49DYDD.


👍️0
deet49 deet49 4 years ago
Delisting to pink sheets can save PMD a fortune in regulatory compliance ...

I feel as though the management is stifling the life out of it they should streamline more maybe take pay cuts in lieu of stock option based on performance there is clearly a no confidence vote taking place in real time via the stock price

just my two little penny's of thought

please do correct me if I am wrong would love to understand better
no one loves a come back story more than me tell me how


👍️0
hempster hempster 4 years ago
guess they all got killed by vaping
👍️0
TradeNaked TradeNaked 5 years ago
$PMD where everybody at? Rock bottom here for a 30-100% bounce
👍️0
Drmicrocap Drmicrocap 11 years ago
Psychemedics Corporation Announces 2013 Earnings Up 28% And Record Revenues
DECLARES 70th CONSECUTIVE QUARTERLY DIVIDEND
PR Newswire Psychemedics Corporation
February 10, 2014 12:03 PM
ACTON, Mass., Feb. 10, 2014 /PRNewswire/ -- Psychemedics Corporation (PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2013. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 21, 2014 to be paid on March 7, 2014. This will be the Company's 70th consecutive quarterly dividend.

(Logo: http://photos.prnewswire.com/prnh/20111107/NE00639LOGO)

The Company's revenue for the year ended December 31, 2013 was $26.9 million versus $25.2 million for the twelve months ended December 31, 2012, an increase of 7%. Net income for the twelve months ended December 31, 2013 was $3.8 million or $0.72 per diluted share, versus $3.0 million or $0.57 per diluted share, for the comparable period last year, an increase of 28%.The Company's revenue for the quarter ended December 31, 2013 was $6.5 million versus $5.7 million for the quarter ended December 31, 2012, an increase of 15%. Net income for the quarter ended December 31, 2013 was $868 thousand or $0.16 per diluted share, versus $273 thousand or $0.05 per diluted share, for the comparable period last year, an increase of 218%.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said,

"2013 was the second consecutive year of record revenues and the Company achieved substantial earnings growth of 28% over 2012. In addition, the Company expanded its product offering in 2013 by building on the technology advances in 2012 with the launch of a hair test for alcohol which looks back at the same 90 day period as our patented drug test. The Company also expanded product offerings through its new partnerships in the instant drug and alcohol testing arena.

"The extraordinary growth in earnings in the fourth quarter compared to 2012 was driven by several factors including an increase in revenues of 15% in 2013, higher than normal expenses in 2012 related to transition costs of new technologies which were implemented in 2012 and did not re-occur in 2013, and a benefit due to a change in the calculation of California income tax. The change in California income tax rate significantly lowered the Company's overall income tax rate. The total benefit was realized in the fourth quarter of 2013 and had a positive impact of approximately $0.05 per diluted share. Without this positive tax impact, our EPS would still have been up 18%.

"With regard to new business, in December 2013, the Company noted that the Brazilian Federal Government had announced new guidelines that will require professional drivers in the transportation industry to pass a hair drug test when obtaining or renewing their driver's license. The first testing is expected to begin on July 1, 2014. We are excited about competing for the hair testing business in Brazil. Psychemedics has a very strong partner in Psychemedics Brasil, a Brazilian-owned independent distributor who we have worked closely with for over 15 years helping a variety of Brazilian organizations work to achieve a drug free workplace. We look forward to continuing to work together on this new opportunity to positively impact public safety as it relates to the transportation industry.

"We are very excited about this opportunity and believe the potential volume from this Brazil opportunity could be very substantial. In order to service that potential volume, we need to make significant investments in plant, equipment and people. These investments must be made in the first half of 2014 to be ready for the July 1 start date. During this period, we will not have any revenues from this Brazil opportunity to offset these costs. Therefore, we would expect earnings in the first half of 2014 to be unfavorably impacted.

"The Company's balance sheet remains strong with approximately $4.0 million in cash and cash equivalents and no long-term debt. Our directors share our confidence in the future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we grow. Therefore, we are pleased to declare our quarterly dividend of $0.15 per share. This dividend represents our 70th consecutive quarterly dividend."

Psychemedics Corporation is the world's largest provider of hair testing for the detection of drugs of abuse. The Company's patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods.

The Psychemedics web site is www.psychemedics.com.

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume, sales and marketing strategies, foreign drug testing laws and regulations, required investments in plant, equipment and people) may be "forward looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the development of markets for new products and services offered, costs of capacity expansion, U.S. and foreign government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.



Psychemedics Corporation
Balance Sheets
(UNAUDITED)


Three Months Ended


Twelve Months Ended

December 31,


December 31,

2013

2012


2013

2012


















Revenues
$6,483,916

$5,658,184


$26,870,297

$25,223,534
Cost of revenues
2,832,154

2,892,745


11,476,263

10,971,886









Gross profit
3,651,762

2,765,439


15,394,034

14,251,648


















Operating Expenses:








General & administrative
1,081,803

1,024,964


4,157,597

3,946,844
Marketing & selling
1,269,713

1,130,210


4,704,970

4,543,598
Research & development
267,091

146,487


825,102

825,518









Total Operating Expenses
2,618,607

2,301,661


9,687,669

9,315,960









Operating income
1,033,155

463,778


5,706,365

4,935,688
Other income
280

447


92,273

1,889









Net income before provision for income taxes
1,033,435

464,225


5,798,638

4,937,577









Provision for income taxes
165,496

191,612


1,993,428

1,957,948









Net income and comprehensive income
$867,939

$272,613


$3,805,210

$2,979,629









Basic net income per share
$0.16

$0.05


$0.72

$0.57









Diluted net income per share
$0.16

$0.05


$0.72

$0.57









Dividends declared per share
$0.15

$0.15


$0.60

$0.60









Weighted average common shares outstanding, basic
5,313,766

5,272,428


5,299,060

5,260,320









Weighted average common shares outstanding, diluted
5,342,509

5,291,370


5,315,463

5,272,542











Psychemedics Corporation
Statements of Income and Comprehensive Income
(UNAUDITED)


December 31,

December 31,

2013

2012




ASSETS



Current Assets:



Cash and cash equivalents
$3,970,512

$3,065,785
Accounts receivable, net of allowance for doubtful accounts



of $144,921 in 2013 and $121,583 in 2012
4,368,864

4,620,768
Prepaid expenses and other current assets
769,269

823,274
Income tax receivable
554,828

854,212
Deferred tax assets
292,795

209,877




Total Current Assets
9,956,268

9,573,916
Fixed Assets, net of accumulated amortization and depreciation



of $5,175,722 in 2013 and $4,395,605 in 2012
6,050,203

4,201,409
Other assets
543,345

345,293




Total Assets
$ 16,549,816

$ 14,120,618




LIABILITIES AND SHAREHOLDERS' EQUITY







Current Liabilities:



Accounts payable
$510,550

$669,789
Accrued expenses
2,447,920

1,413,541




Total Current Liabilities
2,958,470

2,083,330




Deferred tax liabilities, long-term
1,314,221

814,619
Total Liabilities
4,272,691

2,897,949




Shareholders' Equity:



Preferred-stock, $0.005 par value, 872,521 shares authorized,



no shares issued or outstanding
--

--
Common stock, $0.005 par value; 50,000,000 shares authorized



5,981,896 shares issued in 2013 and 5,940,558 shares issued in 2012
29,910

29,703
Additional paid-in capital
28,888,712

28,460,764
Accumulated deficit
(6,559,708)

(7,186,009)
Less - Treasury stock, at cost, 668,130 shares in 2013 and 2012
(10,081,789)

(10,081,789)




Total Shareholders' Equity
12,277,125

11,222,669




Total Liabilities and Shareholders' Equity
$16,549,816

$14,120,618




Contact: Neil Lerner
Vice President of Finance
(978) 206-8220
Neill@psychemedics.com
👍️0
Danstrader Danstrader 11 years ago
What's up with the ask price on td ameritrade 199,999.00 ??? Level 2 shows the next move at 18.25? Still early but it will change by opening bell.
👍️0
Drmicrocap Drmicrocap 12 years ago
http://finance.yahoo.com/news/psychemedics-corporation-announces-3rd-quarter-165200646.html
👍️0
Drmicrocap Drmicrocap 13 years ago
http://finance.yahoo.com/news/sarah-ashby-joins-psychemedics-corporation-142400024.html
👍️0
Penny Roger$ Penny Roger$ 13 years ago
~ Monday! $PMD ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $PMD ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=PMD&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=PMD&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=PMD
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=PMD#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=PMD+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=PMD
Finviz: http://finviz.com/quote.ashx?t=PMD
~ BusyStock: http://busystock.com/i.php?s=PMD&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=PMD >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.
👍️0
Nebuchadnezzar Nebuchadnezzar 13 years ago
how goes it Bucc??

HE*G still trading

hope all is well

been watching PMD for a while now
👍️0
Nebuchadnezzar Nebuchadnezzar 13 years ago
hey buccaneer1961

fancy that, what are the coincidences that we both know about thit little hidden gem

nice yield by the way with this one and steady payout

HE*G is still trading and its almost 2012

-Neb
👍️0
buccaneer1961 buccaneer1961 13 years ago
i wanted to clean up this board and make it much better than it was so i volunteered for mod job
👍️0
buccaneer1961 buccaneer1961 13 years ago
helper,feel free to add info and do accurate dd here so investors can be best informed properly
👍️0
buccaneer1961 buccaneer1961 13 years ago
thankyou,please make sure the dd is correct and true so investors wont be misslead but should have a great understanding of this stock
👍️0
buccaneer1961 buccaneer1961 13 years ago
yes it is,this stock will make investors happy here
👍️0
buccaneer1961 buccaneer1961 13 years ago
if theres knowledgible holders that have exp. with this co. please pm me,looking for assist mod. with insight on this company that can provide accurate dd on this co. and add to the stickies for shareholders insight as well
👍️0
buccaneer1961 buccaneer1961 13 years ago
thankyou for asking to stay on board as asist
👍️0
buccaneer1961 buccaneer1961 13 years ago
hello friend,yes,its a great play
👍️0
buccaneer1961 buccaneer1961 13 years ago
ok,thankyou for the email,i was misinformed badly,this stock will be very good,look at the sales,the products etc. no fluff pr. or stuff like that!
👍️0
buccaneer1961 buccaneer1961 13 years ago
theres always bagholders especially if theres a pump without merits
👍️0
buccaneer1961 buccaneer1961 13 years ago
is there pumpers or paid fluff promos?
👍️0
BIG bhapa BIG bhapa 13 years ago
lol, it's still going to be an interesting play.
👍️0
marknn1985 marknn1985 13 years ago
Tell that to the people who got in at $11
👍️0
BIG bhapa BIG bhapa 13 years ago
more DD is coming.
👍️0
BIG bhapa BIG bhapa 13 years ago
fundamentals indicate stabilization of the stock.
👍️0
BIG bhapa BIG bhapa 13 years ago
Cannabis is used by PMD in some forms of drugs.
👍️0
BIG bhapa BIG bhapa 13 years ago
PMD is a good play!!
👍️0